Oncorus is a clinical-stage biopharmaceutical company focused on developing viral immunotherapies to transform outcomes for cancer patients. Co.'s primary product candidate ONCR-177, is an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform. Co. has developed its Phase 1 clinical trial of ONCR-177 in patients with solid tumors, including breast cancers and cutaneous tumors. Co. is also developing a pipeline of product candidates that utilizes Co.'s second platform, its selectively self-amplifying viral RNA, immunotherapy platform, which aims to enable repeat intravenous, administration of viral immunotherapies to treat cancers. The ONCR stock yearly return is shown above.
The yearly return on the ONCR stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ONCR annual return calculation with any dividends reinvested as applicable (on ex-dates).
|